Breaking News

Japan's Topix Index Extends Gain to 4%
Tweet TWEET

Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results

Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results

Conference Call at 7:30 am Eastern Time Today

VANCOUVER, British Columbia, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Tekmira
Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of
RNA interference (RNAi) therapeutics, announced today its financial and
operating results for the third quarter ended September 30, 2012 and provided
a corporate update.

On November 12, 2012, Tekmira announced that it entered into a settlement
agreement with Alnylam Pharmaceuticals, Inc. that resolves all litigation
between the companies, and signed a new licensing agreement that restructures
the relationship and provides clarity on all intellectual property and
licensing issues between the companies. As a result of the restructuring and
new agreements, Tekmira will receive $65 million within 10 days and is
eligible to receive $10 million in near-term milestone payments expected to be
received in 2013. For more information, please refer to Tekmira's news release
dated November 12, 2012.

"The settlement and restructuring announced yesterday gives us, and the entire
RNAi field, clarity around the intellectual property that protects our lipid
nanoparticle (LNP) technology. Building upon our strong balance sheet and
accomplishments to date, we are confident that we can continue to create
significant, sustainable value for our shareholders. With our cash runway now
extending into 2015, we are excited about our plans to aggressively advance
multiple products into human clinical trials," said Dr. Mark J. Murray,
Tekmira's President and CEO.

"We recognize that the primary value driver for Tekmira will be the clear
demonstration of the clinical value of our own pipeline of RNAi products in a
range of therapeutically important, commercially attractive markets. We expect
that our lead oncology product, TKM-PLK1, will enter a Phase 2 trial in 2013;
we continue to advance our TKM-Ebola product in collaboration with the U.S.
Department of Defense's TMT program; and, we continue to generate data to
support near-term decisions around further development of other product
candidates within our pipeline. In addition, we are entitled to future royalty
payments based on sales of Marqibo, which was recently approved by the FDA,"
added Dr. Murray.

Tekmira's Products

TKM-PLK1

In December 2010, Tekmira announced the initiation of patient dosing in a
Phase 1 human clinical trial for TKM-PLK1 in patients with advanced solid
tumors. The Phase 1 clinical trial, conducted at oncology centers in the
United States, is an open label, multi-dose, dose escalation study designed to
evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1 as well as
determine the maximum tolerated dose. Secondary objectives of the trial are to
measure tumor response and the pharmacodynamic effects of TKM-PLK1 in patients
providing biopsies.

To date, TKM-PLK1 has been administered to 23 patients with a total of 128
doses administered. On August 14, 2012, Tekmira released interim results from
the TKM-PLK1 Phase 1 study, which employs a unique LNP developed for oncology
applications, showing that TKM-PLK1 was generally well tolerated. TKM-PLK1 has
shown drug activity to date, including one patient with a partial response and
another patient who attained stable disease. Based on these interim data,
patient enrollment is continuing at 0.75 mg/kg. Once complete, results from
the Phase 1 clinical trial, including additional measures of drug activity,
will be presented at a forthcoming scientific meeting. Tekmira anticipates
initiating a Phase 2 clinical trial in 2013.

TKM-Ebola Update

On August 6, 2012, Tekmira announced that it had received a temporary
stop-work order from the U.S. Department of Defense (DoD) with respect to
Tekmira's TKM-Ebola program, which is funded under the Transformational
Medical Technologies (TMT) Program. On October 2, 2012, Tekmira disclosed that
the temporary stop-work order was lifted by the United States DoD and work
will continue on development of the TKM-Ebola product.

Tekmira has submitted a modification request to the existing contract to the
U.S. DoD in order to integrate recent advancements in LNP formulation and
manufacturing technology in the TKM-Ebola development program. The program
will utilize an LNP formulation that is more than 10-fold more potent than
previous formulations and more potent than all other LNP formulations
currently being evaluated in clinical trials. Tekmira has initiated
pre-clinical and chemistry, manufacturing and control studies that support the
use of these improvements in the program. This development strategy will be
accommodated by modifications to the existing contract, allowing both Tekmira
and TMT to benefit from the significant advancements in LNP formulation
technology made by Tekmira since the commencement of the TMT-funded program in
July 2010. It is expected that the LNP formulation work will be completed and
submitted to the FDA in the second half of 2013 in order to initiate a new
Phase 1 clinical trial.

Other Preclinical Candidates

Tekmira has a number of other preclinical candidates in its pipeline
addressing a wide range of therapeutic needs such as alcohol dependence and
additional oncology targets. The research team at Tekmira will continue to
generate data to support the advancement of the most promising of these
targets and expects to be in a position to nominate the next product candidate
for development in the coming months.

Partners' Products

As dictated by the terms in the new licensing agreement announced yesterday,
Alnylam has a license to use Tekmira's LNP technology to advance RNAi
therapeutic products, and Tekmira remains eligible to receive milestones and
royalties as Alnylam's LNP enabled products are developed and commercialized.

  *ALN-TTR: Tekmira is entitled to receive a $5 million milestone payment
    when ALN-TTR02 enters a pivotal or Phase 3 clinical trial, which is
    expected to occur in 2013. Tekmira is eligible to receive royalty payments
    based on commercial sales of ALN-TTR.
  *ALN-VSP: Tekmira is entitled to receive a $5 million milestone payment
    related to the initiation of clinical trials for ALN-VSP in China, which
    is expected to occur in 2013. Tekmira is eligible to receive royalty
    payments based on commercial sales of ALN-VSP.
  *ALN-PCS: Tekmira is eligible to receive royalty payments based on
    commercial sales of ALN-PCS.
  *Other LNP-Enabled Products: Tekmira is eligible to receive up to an
    aggregate of $16 million in milestones and royalties for each additional
    LNP-based product developed by Alnylam.

Tekmira has a number of legacy license agreements that provide potential
milestone and royalty payments. Marqibo, which is a liposomal formulation of
the chemotherapy drug vincristine – along with two other liposomal
chemotherapy products, Alocrest and Brakiva – were licensed from Tekmira to
Talon Therapeutics, Inc. in 2006. Talon is responsible for all future
development of these products. On August 9, 2012, Tekmira disclosed that Talon
received accelerated approval from the FDA for Marqibo® (vinCRIStine sulfate
LIPOSOME injection) for the treatment of adult patients with Philadelphia
chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or
greater relapse or whose disease has progressed following two or more
anti-leukemia therapies. Tekmira received a US$1 million milestone payment
based on the FDA approval of Marqibo and is eligible to receive royalty
payments based on Marqibo's commercial sales.

Financial Results

Net Loss

For the first nine months of 2012 (year-to-date (YTD) 2012) the Company's net
loss was $8.5 million ($0.63 per common share) as compared to a net loss of
$8.1 million ($0.73 per common share) for YTD 2011. For Q3 2012, net loss was
$3.4 million ($0.25 per common share) as compared to a Q3 2011 net loss of
$1.5 million ($0.12 per common share).

Revenue

Revenue was $3.0 million in Q3 2012 as compared to $4.2 million in Q3 2011.

On July 14, 2010, Tekmira signed a contract with the United States Government
to advance an RNAi therapeutic utilizing the Tekmira's LNP technology to treat
Ebola virus infection. Under the contract Tekmira is being reimbursed for
costs incurred, including an allocation of overheads, and is being paid an
incentive fee. U.S. Government revenue was $1.9 million in Q3 2012 as compared
to $2.0 million in Q3 2011.

On August 6, 2012, the Company announced that it had received a temporary
stop-work order from the U.S. Government in respect of its TKM-Ebola contract.
On October 2, 2012, Tekmira announced that the stop-work order had been lifted
and work was to be resumed. As a result of the stop-work order, U.S.
Government revenue was lower than the Company had forecasted for Q3 2012 and
YTD 2012.

In Q3 2012, the Company earned a US$1.0 million milestone payment from Talon
Therapeutics, Inc. based on the FDA approval of Marqibo and will receive
royalty payments based on Marqibo's commercial sales.

Research, development, collaborations and contracts expenses

Research, development, collaborations and contracts expenses were $3.1 million
in Q3 2012 as compared to $4.4 million in Q3 2011.

Third-party expenses on the TKM-Ebola program and Alnylam manufacturing were
considerably lower in Q3 2012 as compared to Q3 2011.

Spending on Tekmira's internal research programs was reduced as the Company
focused on TKM-Ebola, TKM-PLK1 and its litigation against Alnylam and AlCana.

General and administrative expenses

General and administrative expenses were $1.5 million in Q3 2012 as compared
to $1.2 million in Q3 2011.

The increase in Q3 2012 largely relates to legal fees incurred in respect of
Tekmira's lawsuit against Alnylam and AlCana.

As at September 30, 2012, the Company had a contingent obligation to Orrick,
Herrington and Sutcliffe LLP (Orrick), lead legal counsel for the lawsuit
against Alnylam and AlCana of $15,620,961 (US$15,887,877). As a result of the
settlement of the litigation between Tekmira and Alnylam on November 12, 2012
this amount, plus costs incurred after September 30, 2012, are now payable to
Orrick and will be recorded in Q4 2012.

Other income (losses) - change in fair value of warrant liability

In conjunction with equity and debt financing transactions in 2011 and an
equity private placement that closed on February 29, 2012, Tekmira has issued
common share purchase warrants. Under Tekmira's accounting policy, at each
balance sheet date, the warrants are revalued using the Black-Scholes model
and the change in value is recorded in the consolidated statement of
operations and comprehensive loss. The aggregate increase in value of
Tekmira's common share purchase warrants in Q3 2012 was $1.7 million. The
increase is largely a result of the increase in the Company's share price from
the previous balance sheet date of June 30, 2012.

Financial guidance

Tekmira believes that current funds on hand, plus expected income, including
payments to be received from Alnylam in Q4 2012 and other funds from
collaborative partners and the U.S. Government, will be sufficient to continue
product development into 2015.

Conference Call Information

Tekmira will hold a conference call and webcast today (Tuesday, November 13,
2012) at 4:30 am Pacific Time (7:30 am Eastern Time) to discuss its third
quarter 2012 results and a corporate update, including the settlement
announced yesterday. A live webcast of the call can be accessed through the
Investor section of Tekmira's website at www.tekmirapharm.com. Or,
alternatively, to dial into the conference call, please call 914-495-8556 or
1-866-393-1607 and reference conference ID 70796137.

An archived webcast of this conference call will be available on the Tekmira
website approximately two hours after the event. Or alternatively, you may
access a replay of the conference call by calling 404-537-3406 or
1-855-859-2056 and referencing conference ID 70796137.

About RNAi and Tekmira's LNP

RNAi therapeutics have the potential to treat a broad number of human diseases
by "silencing" disease causing genes. The discoverers of RNAi, a gene
silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for
Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery
technology to be effective systemically. Tekmira believes its LNP technology
represents the most widely adopted delivery technology for the systemic
delivery of RNAi therapeutics. Tekmira's LNP platform is being utilized in
multiple clinical trials by both Tekmira and its partners. Tekmira's LNP
technology (formerly referred to as stable nucleic acid-lipid particles or
SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles
that are effective in delivering RNAi therapeutics to disease sites in
numerous preclinical models. Tekmira's LNP formulations are manufactured by a
proprietary method which is robust, scalable and highly reproducible, and
LNP-based products have been reviewed by multiple FDA divisions for use in
clinical trials. LNP formulations comprise several lipid components that can
be adjusted to suit the specific application.

About Alnylam RNAi Technology

Tekmira has licenses to Alnylam RNAi intellectual property for certain siRNA
programs.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on
advancing novel RNAi therapeutics and providing its leading lipid nanoparticle
delivery technology to pharmaceutical partners. Tekmira has been working in
the field of nucleic acid delivery for over a decade and has broad
intellectual property covering LNPs. Further information about Tekmira can be
found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8319

Forward-Looking Statements and Information

This news release contains "forward-looking statements" or "forward-looking
information" within the meaning of applicable securities laws (collectively,
"forward-looking statements"). Forward-looking statements are generally
identifiable by use of the words "believes," "may," "plans," "will,"
"anticipates," "intends," "budgets," "could," "estimates," "expects,"
"forecasts," "projects" and similar expressions, and the negative of such
expressions. Forward-looking statements in this news release include
statements about the settlement to resolve all litigation between Tekmira and
Alnylam Pharmaceuticals, Inc. and AlCana Technologies, Inc; statements about
the quantum and timing of Tekmira's expected payments related to the
settlement agreement and new licensing agreement with Alnylam; statements
about Tekmira's expected payments from the settlement and cash runway
extending into 2015; Tekmira's plans to advance multiple products into human
clinical trials; expected timing of Phase 2 clinical trials for TKM-PLK1; the
development of other product candidates in Tekmira's pipeline, including the
expected timing for the nomination of Tekmira's next product candidate;
anticipated royalty payments based on sales of Marqibo; the modification
request to the existing TKM-Ebola contract with the DoD to integrate recent
advancements in LNP formulation and manufacturing technology; expected timing
of the completion and submission of the LNP formulation work to the FDA and
the initiation of a new Phase 1 clinical trial; the quantum and timing of
funding that may be provided to Tekmira pursuant to the TKM-Ebola contract
with the DoD; the quantum and timing of future milestone royalty payments
expected from the ALN-TTR02, ALN-VSP, ALN-PCS and other LNP-enabled product
development programs of Alnylam; the timing of an ALN-TTR02 pivotal or Phase 3
clinical trial; the timing of ALN-VSP clinical trials in China; milestones and
royalty payments from Alnylam's LNP-enabled products; Tekmira's expectations
of entering into a cross license agreement with AlCana, which includes
anticipated milestone and royalty payments and an expected agreement for
AlCana not to compete in the RNAi field for five years; licenses for the
discovery, development and commercialization of RNAi products directed to
thirteen gene targets; expected royalty payments from commercial sales of
Tekmira's product development partners; and Tekmira's strategy, future
operations, clinical trials, prospects and the plans of management; RNAi
(ribonucleic acid interference) product development programs; estimates of the
number of clinical development programs to be undertaken by Tekmira and its
product development partners; selection of additional product candidates;
timing of release of clinical data; the effects of Tekmira's products on the
treatment of cancer and infectious disease; statements and details of the
TKM-PLK1 and TKM-Ebola Phase 1 human clinical trials; the quantum and timing
of potential funding; use of lipid nanoparticle (LNP) technology by Tekmira's
licensees; Tekmira's expectations with respect to existing and future
agreements with third parties; and estimates of the length of time Tekmira's
business will be funded by its anticipated financial resources.

With respect to the forward-looking statements contained in this news release,
Tekmira has made numerous assumptions regarding, among other things: LNP's
status as a leading RNAi delivery technology; the effectiveness of Tekmira's
products as a treatment for cancer or infectious disease; the developmental
milestones and approvals required to trigger funding for TKM-Ebola from the
TMT program; results in preclinical models are indicative of the potential
effect in humans; Tekmira's research and development capabilities and
resources; FDA approval with respect to commencing clinical trials; the timing
and obtaining of regulatory approvals for Tekmira's products; the timing and
results of clinical data releases and use of LNP technology by Tekmira's
development partners and licensees; the time required to complete research and
product development activities; the timing and quantum of payments to be
received under contracts with Tekmira's partners including Alnylam, Talon, the
DoD, and others; Tekmira's financial position and its ability to execute on
its business strategy; and Tekmira's ability to protect its intellectual
property rights and not to infringe on the intellectual property rights of
others. While Tekmira considers these assumptions to be reasonable, these
assumptions are inherently subject to significant business, economic,
competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause
Tekmira's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements contained herein. Known risk factors
include, among others: expected payments related to the settlement
andlicensing agreement between Tekmira and Alnylam may not be received in the
quantum and on the timing currently anticipated, or at all; payments received
from the settlement may not be sufficient to fund Tekmira's continued business
plan as currently anticipated; TKM-PLK1 may never enter into Phase 2 clinical
trials; Tekmira may never receive milestones or royalty payments from Alnylam;
Tekmira may not receive any additional non-exclusive licenses; the possibility
that Tekmira does not enter into a cross license agreement with AlCana on the
terms currently anticipated, or all; Tekmira's ability to obtain and protect
intellectual property rights, and operate without infringing on the
intellectual property rights of others; Tekmira's research and development
capabilities and resources will not meet current or expected demand; Tekmira's
development partners and licensees conducting clinical trial, development
programs and joint venture strategic alliances will not result in expected
results on a timely basis, or at all; anticipated payments under contracts
with Tekmira's collaborative partners may not be received by Tekmira on a
timely basis, or at all, or in the quantum expected by Tekmira; Tekmira's
products may not prove to be effective in the treatment of cancer
andinfectious disease; the possibility that other organizations have made
advancements in RNAi delivery technology that Tekmira is not aware of; the FDA
will not approve the commencement of Tekmira's planned clinical trials or
approve the use of Tekmira's products and generally, difficulties or delays in
the progress, timing and results of clinical trials; the FDA may determine
that the design and planned analysis of Tekmira's clinical trials do not
adequately address the trial objectives in support of Tekmira's regulatory
submissions; future operating results are uncertain and likely to fluctuate;
competition from other pharmaceutical or biotechnology companies; Tekmira's
ability to raise additional financing required to fund further research and
development, clinical studies, and obtain regulatory approvals, on
commercially acceptable terms or at all; economic and capital market
conditions; a pivotal trial for ALN-TTR02 may not start as currently
anticipated, or at all; clinical trials for ALN-VSP may not commence as
anticipated, or at all; anticipated payments under contracts with Tekmira's
collaborative partners including the U.S. Government, Alnylam, and Talon will
not be received by Tekmira on a timely basis, or at all, or in the quantum
expected by Tekmira; the U.S. Government may reduce or cancel certain defense
spending, including Tekmira's contract to develop TKM-Ebola; FDA may decide
that TKM-Ebola "Animal Rule" data is insufficient for approval and require
additional pre-clinical, clinical or other studies, refuse to approve
TKM-Ebola, or place restrictions on our ability to commercialize TKM-Ebola;
the release of data from the TKM-Ebola and TKM-PLK1 Phase 1 human clinical
trials may not occur in the expected timeframe, or at all; the DoD may not
accept the modification request to the existing TKM-Ebola to integrate recent
advancements in LNP formulation and manufacturing technology; we may not
complete the work necessary for the submission of the new LNP formulation to
the FDA in the anticipate timeframe, or at all;we may not initiate a new
TKM-Ebola Phase 1 clinical trial in the anticipated timeframe, or at all;
pre-clinical and clinical trials may be more costly or take longer to complete
than anticipated; pre-clinical or clinical trials may not generate results
that warrant future development of the tested drug candidate; Tekmira's
products may not prove to be effective in the treatment of cancer
orinfectious disease; Tekmira may become subject to product liability or
other legal claims for which Tekmira has made no accrual in its financial
statements; Tekmira's cash runway may not extend as far as anticipated, and
may be substantially less than required to continue current operations; and
the possibility that Tekmira has not sufficiently budgeted for expenditures
necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira
appears in Tekmira's annual report on Form 20-F for the year ended December
31, 2011 (Annual Report), which is available at www.sedar.com or at
www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified
in their entirety by this cautionary statement, and Tekmira disclaims any
obligation to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or developments,
except as required by law.

Marqibo is a U.S. registered trademark of Talon Therapeutics, Inc.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com
        
         Media
         David Ryan
         Longview Communications Inc.
         Phone: 416-649-8007
         Email: dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo
 
Press spacebar to pause and continue. Press esc to stop.